Edwards Lifesciences (NYSE:EW) Updates FY 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.400-2.500 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $5.6 billion-$6.0 billion, compared to the consensus revenue estimate of $5.8 billion. Edwards Lifesciences also updated its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Trading Up 6.9 %

Shares of EW stock opened at $75.83 on Thursday. The firm has a market capitalization of $44.72 billion, a PE ratio of 10.94, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a fifty day moving average of $72.51 and a two-hundred day moving average of $69.36.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, research analysts expect that Edwards Lifesciences will post 2.56 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on EW. Citigroup lifted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $79.86.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.